首页 > 最新文献

European review for medical and pharmacological sciences最新文献

英文 中文
Retraction Note: Fas/FasL induces myocardial cell apoptosis in myocardial ischemia-reperfusion rat model. 撤稿说明:Fas/FasL 在心肌缺血再灌注大鼠模型中诱导心肌细胞凋亡。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-07-01 DOI: 10.26355/eurrev_202407_36516
X-M Liu, Z-M Yang, X-K Liu

The article "Fas/FasL induces myocardial cell apoptosis in myocardial ischemia-reperfusion rat model", by X.-M. Liu, Z.-M. Yang, X.-K. Liu, published in Eur Rev Med Pharmacol Sci 2017; 21 (12): 2913-2918- PMID: 28682425 has been retracted by the Editor in Chief. Following some concerns raised on PubPeer (link: https://pubpeer.com/publications/29CE1A59A8180E414855FA3871BCAC), the Editor in Chief has started an investigation to assess the validity of the results as well as possible figure manipulation. The authors were informed about the journal's investigation but remained unresponsive and have not provided the manuscript's raw data. The journal's investigation revealed a figure overlap between panels 10 U/mL and 100 U/mL in Figure 1. Consequently, the Editor in Chief mistrusts the results presented and has decided to retract the article. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/12953.

文章 "Fas/FasL 在心肌缺血再灌注大鼠模型中诱导心肌细胞凋亡",作者:X.-M. Liu, Z.-M.Liu, Z.-M.Yang, X.-K.Liu, published in Eur Rev Med Pharmacol Sci 2017; 21 (12):2913-2918- PMID: 28682425 已被主编撤回。在PubPeer(链接:https://pubpeer.com/publications/29CE1A59A8180E414855FA3871BCAC)上提出了一些问题后,主编已开始调查,以评估结果的有效性以及可能存在的数字操纵。本刊已将调查情况告知作者,但作者仍未做出回应,也未提供稿件的原始数据。期刊调查发现,图 1 中 10 U/mL 和 100 U/mL 两个板块的数据有重叠。因此,主编对所提供的结果不信任,决定撤稿。本文已被撤稿。https://www.europeanreview.org/article/12953。
{"title":"Retraction Note: Fas/FasL induces myocardial cell apoptosis in myocardial ischemia-reperfusion rat model.","authors":"X-M Liu, Z-M Yang, X-K Liu","doi":"10.26355/eurrev_202407_36516","DOIUrl":"https://doi.org/10.26355/eurrev_202407_36516","url":null,"abstract":"<p><p>The article \"Fas/FasL induces myocardial cell apoptosis in myocardial ischemia-reperfusion rat model\", by X.-M. Liu, Z.-M. Yang, X.-K. Liu, published in Eur Rev Med Pharmacol Sci 2017; 21 (12): 2913-2918- PMID: 28682425 has been retracted by the Editor in Chief. Following some concerns raised on PubPeer (link: https://pubpeer.com/publications/29CE1A59A8180E414855FA3871BCAC), the Editor in Chief has started an investigation to assess the validity of the results as well as possible figure manipulation. The authors were informed about the journal's investigation but remained unresponsive and have not provided the manuscript's raw data. The journal's investigation revealed a figure overlap between panels 10 U/mL and 100 U/mL in Figure 1. Consequently, the Editor in Chief mistrusts the results presented and has decided to retract the article. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/12953.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author Correction: Momordica charantia reduced ovarian ischemia - reperfusion injury by suppressing APAF-1 expression. 作者更正:桃金娘通过抑制 APAF-1 的表达减轻卵巢缺血再灌注损伤
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-07-01 DOI: 10.26355/eurrev_202407_36586
F Aşır, Ç Özgökce

Eur Rev Med Pharmacol Sci 2023; 27 (6): 2182-2188-DOI: 10.26355/eurrev_202303_31751-PMID: 37013735, published on March 30, 2023. After publication, the authors have contacted the journal to correct and update information contained in the Acknowledgments section. Therefore, the Acknowledgments are corrected as follows: • This study was supervised by Prof. Dr. Engin Deveci. He has agreed and accepted the final version of the published article. All authors, including Prof. Dr. Engin Deveci, have agreed to this change and provided a confirmation letter signed by all parties. https://www.europeanreview.org/article/31751 There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause.

Eur Rev Med Pharmacol Sci 2023; 27 (6):2182-2188-DOI:10.26355/eurrev_202303_31751-PMID:37013735,发表于 2023 年 3 月 30 日。文章发表后,作者已联系本刊,要求更正和更新致谢部分的信息。因此,致谢部分更正如下:- 本研究由 Engin Deveci 教授博士指导。他已同意并接受所发表文章的最终版本。包括 Engin Deveci 教授在内的所有作者都同意这一修改,并提供了各方签署的确认函。https://www.europeanreview.org/article/31751 本文有修改之处。出版商对此造成的不便深表歉意。
{"title":"Author Correction: Momordica charantia reduced ovarian ischemia - reperfusion injury by suppressing APAF-1 expression.","authors":"F Aşır, Ç Özgökce","doi":"10.26355/eurrev_202407_36586","DOIUrl":"https://doi.org/10.26355/eurrev_202407_36586","url":null,"abstract":"<p><p>Eur Rev Med Pharmacol Sci 2023; 27 (6): 2182-2188-DOI: 10.26355/eurrev_202303_31751-PMID: 37013735, published on March 30, 2023. After publication, the authors have contacted the journal to correct and update information contained in the Acknowledgments section. Therefore, the Acknowledgments are corrected as follows: • This study was supervised by Prof. Dr. Engin Deveci. He has agreed and accepted the final version of the published article. All authors, including Prof. Dr. Engin Deveci, have agreed to this change and provided a confirmation letter signed by all parties. https://www.europeanreview.org/article/31751 There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adiponectin and leptin profiles among obese pregnant women with preeclampsia vs. non-preeclampsia: a systematic review and meta-analysis. 先兆子痫与非先兆子痫肥胖孕妇的脂肪连接蛋白和瘦素概况:系统综述和荟萃分析。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-07-01 DOI: 10.26355/eurrev_202407_36524
A D Nugrahani, M A Aziz, D P J Santoso, A Siddiq, A Y Pramatirta, S Irianti, A Pribadi, A D Anwar, M R A A Syamsunarno

Objective: Preeclampsia (PE) affects only about 10% of women who meet the criteria for obesity based on their body mass index (BMI). Obesity is suggested to play a role in preeclampsia pathophysiology, and in addition to BMI, associated biomarkers with higher sensitivity and specificity, such as with adipokines from adipose tissue, are needed to enable clinical risk assessment. This study aimed to investigate obese pregnant women with and without PE by comparing clinical profiles and adipokine profiles specific to general adipose tissue (adiponectin and leptin).

Materials and methods: This meta-analysis was conducted following the PRISMA and was registered in PROSPERO (CRD42023478706). We utilized Cochrane, Scopus, and PubMed/Medline databases. The Cochrane ROBINS-I instrument was employed to assess the quality of studies. Pooled standard mean difference (SMD) and p-value were analyzed using a random-effects model with the DerSimonian-Laird method, while subgroup analysis with the Chi-square test and the inconsistency index (I2) were used to assess potential sources of heterogeneity.

Results: Three observational studies included a total of 2,646 obese pregnant women and found that adiponectin was more likely to have a lower level in pregnant women with obesity [SMD=-0.32; 95% CI: -0.34-0.17, p=0.003] and leptin was more likely to be higher in obese pregnant women with PE rather than non-PE [SMD=0.53; 95% CI: -0.19-1.08, p<0.00001].

Conclusions: Adiponectin levels were more likely to be lower in pregnant women with obesity in the PE group than in the non-PE group, and leptin levels were more likely to be higher.

目的:子痫前期(PE)患者中只有约 10%的妇女根据体重指数(BMI)符合肥胖标准。肥胖被认为在子痫前期的病理生理学中起作用,除了体重指数外,还需要灵敏度和特异性更高的相关生物标志物,如来自脂肪组织的脂肪因子,以进行临床风险评估。本研究旨在通过比较临床特征和一般脂肪组织特有的脂肪因子特征(脂肪连素和瘦素),对患有和未患有 PE 的肥胖孕妇进行调查:本荟萃分析按照 PRISMA 标准进行,并在 PROSPERO(CRD42023478706)上进行了注册。我们使用了 Cochrane、Scopus 和 PubMed/Medline 数据库。采用 Cochrane ROBINS-I 工具评估研究质量。使用随机效应模型和 DerSimonian-Laird 方法分析了汇总的标准平均差(SMD)和 p 值,同时使用 Chi-square 检验和不一致指数(I2)进行了亚组分析,以评估潜在的异质性来源:三项观察性研究共纳入了2646名肥胖孕妇,结果发现肥胖孕妇的脂肪连素水平更有可能较低[SMD=-0.32;95% CI:-0.34-0.17,p=0.003],而患有PE的肥胖孕妇的瘦素水平更有可能高于非PE孕妇[SMD=0.53;95% CI:-0.19-1.08,p结论:肥胖孕妇的脂肪连素水平更有可能较低,而患有PE的肥胖孕妇的瘦素水平更有可能高于非PE孕妇[SMD=0.53;95% CI:-0.19-1.08,p=0.003]:与非 PE 组相比,PE 组肥胖孕妇的脂肪连通素水平更可能较低,而瘦素水平更可能较高。
{"title":"Adiponectin and leptin profiles among obese pregnant women with preeclampsia vs. non-preeclampsia: a systematic review and meta-analysis.","authors":"A D Nugrahani, M A Aziz, D P J Santoso, A Siddiq, A Y Pramatirta, S Irianti, A Pribadi, A D Anwar, M R A A Syamsunarno","doi":"10.26355/eurrev_202407_36524","DOIUrl":"10.26355/eurrev_202407_36524","url":null,"abstract":"<p><strong>Objective: </strong>Preeclampsia (PE) affects only about 10% of women who meet the criteria for obesity based on their body mass index (BMI). Obesity is suggested to play a role in preeclampsia pathophysiology, and in addition to BMI, associated biomarkers with higher sensitivity and specificity, such as with adipokines from adipose tissue, are needed to enable clinical risk assessment. This study aimed to investigate obese pregnant women with and without PE by comparing clinical profiles and adipokine profiles specific to general adipose tissue (adiponectin and leptin).</p><p><strong>Materials and methods: </strong>This meta-analysis was conducted following the PRISMA and was registered in PROSPERO (CRD42023478706). We utilized Cochrane, Scopus, and PubMed/Medline databases. The Cochrane ROBINS-I instrument was employed to assess the quality of studies. Pooled standard mean difference (SMD) and p-value were analyzed using a random-effects model with the DerSimonian-Laird method, while subgroup analysis with the Chi-square test and the inconsistency index (I2) were used to assess potential sources of heterogeneity.</p><p><strong>Results: </strong>Three observational studies included a total of 2,646 obese pregnant women and found that adiponectin was more likely to have a lower level in pregnant women with obesity [SMD=-0.32; 95% CI: -0.34-0.17, p=0.003] and leptin was more likely to be higher in obese pregnant women with PE rather than non-PE [SMD=0.53; 95% CI: -0.19-1.08, p<0.00001].</p><p><strong>Conclusions: </strong>Adiponectin levels were more likely to be lower in pregnant women with obesity in the PE group than in the non-PE group, and leptin levels were more likely to be higher.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brain targeting efficacy of novel drug delivery system in the treatment of Alzheimer's disease. 新型给药系统在治疗阿尔茨海默病中的脑靶向疗效。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-07-01 DOI: 10.26355/eurrev_202407_36521
L-H Duan, L-I Li, C-B Wang, Q-Q Liu, X Zhang, Z-Z Wu

Objective: Alzheimer's disease (AD), a common degenerative disease of the central nervous system in the elderly, has become the third largest health killer after cardiovascular and cerebrovascular diseases and tumors. Based on the fact that Alzheimer's disease is a disease with multiple etiologies and complex pathology, a single target is bound to have a limited curative effect, and the synergy of multiple links and multiple targets is expected to achieve a better curative effect. The aim of this study is to investigate the brain targeting of a drug modified by chitosan, based on the new nanodrug delivery system for treating Alzheimer's disease developed by the research group.

Materials and methods: Chitosan with good biocompatibility, biosorption, and degradation products that can protect and promote the regeneration of nerve cells was selected to combine with galantamine, a natural representative cholinesterase inhibitor, to develop a new nano drug delivery system for nasal delivery of anti-Alzheimer's disease with a multi-target synergistic effect. Synchronous analysis was conducted on the blood and brain tissue drug concentrations after intravenous and nasal administration of the original drug solution and system solution. The brain targeting index (DTI) is used to evaluate the brain targeting effect of the nano-drug delivery system after intranasal administration.

Results: The blood concentration of galantamine original drug solution and galantamine system solution after intravenous injection and nasal show that in the two administration methods of intravenous injection and nasal administration, under the same administration method, the time point of the system reaching the highest blood drug concentration is much higher than that of the original drug. The content of galantamine in plasma samples and tissue samples indicate that after intravenous administration and intranasal administration of the galantamine system, at the same time point, the drug concentration in brain tissue was far greater than that of the original drug of galantamine, and the duration was also longer. The concentration of drugs in brain tissue decreased gradually in the order of olfactory bulb, olfactory tract, brain, and cerebellum. In the brain tissues of the olfactory bulb, olfactory tract, cerebrum, and cerebellum, the drug concentration of the galantamine system after intravenous injection is lower than that after nasal administration.

Conclusions: This study concludes that compared with the original drug solution, the nano drug delivery system has significant brain targeting for nasal administration, and intravenous injection also has brain targeting. In the olfactory bulb, olfactory tract, brain, and cerebellum, the brain targeting index at the olfactory bulb is the highest, and the targeting is the best.

目的:阿尔茨海默病(Alzheimer's disease,AD)是老年人常见的中枢神经系统退行性疾病,已成为继心脑血管疾病和肿瘤之后的第三大健康杀手。基于阿尔茨海默病是一种病因多、病理复杂的疾病,单一靶点的疗效必然有限,多环节、多靶点协同有望取得更好的疗效。本研究的目的是在课题组开发的治疗阿尔茨海默病的新型纳米给药系统的基础上,研究经壳聚糖修饰的药物的脑靶向性:选择具有良好生物相容性、生物吸附性和降解产物,可保护和促进神经细胞再生的壳聚糖,与天然代表性胆碱酯酶抑制剂加兰他敏结合,开发出具有多靶点协同效应的鼻腔给药抗阿尔茨海默病新型纳米给药系统。对原药溶液和系统溶液静脉和鼻腔给药后的血液和脑组织药物浓度进行了同步分析。用脑靶向指数(DTI)来评价纳米给药系统鼻内给药后的脑靶向效应:静脉注射和鼻腔给药后加兰他敏原药溶液和加兰他敏系统溶液的血药浓度显示,在静脉注射和鼻腔给药两种给药方法中,在相同给药方法下,系统达到最高血药浓度的时间点远高于原药。血浆样本和组织样本中的加兰他敏含量表明,静脉注射和鼻腔内给药加兰他敏体系后,在同一时间点,脑组织中的药物浓度远高于加兰他敏原药,持续时间也更长。脑组织中的药物浓度按照嗅球、嗅束、大脑和小脑的顺序逐渐降低。在嗅球、嗅束、大脑和小脑的脑组织中,静脉注射后加兰他敏系统的药物浓度低于鼻腔给药后的药物浓度:本研究得出结论:与原药液相比,纳米给药系统鼻腔给药具有显著的脑靶向性,静脉注射也具有脑靶向性。在嗅球、嗅道、大脑和小脑中,嗅球的脑靶向指数最高,靶向性最好。
{"title":"Brain targeting efficacy of novel drug delivery system in the treatment of Alzheimer's disease.","authors":"L-H Duan, L-I Li, C-B Wang, Q-Q Liu, X Zhang, Z-Z Wu","doi":"10.26355/eurrev_202407_36521","DOIUrl":"https://doi.org/10.26355/eurrev_202407_36521","url":null,"abstract":"<p><strong>Objective: </strong>Alzheimer's disease (AD), a common degenerative disease of the central nervous system in the elderly, has become the third largest health killer after cardiovascular and cerebrovascular diseases and tumors. Based on the fact that Alzheimer's disease is a disease with multiple etiologies and complex pathology, a single target is bound to have a limited curative effect, and the synergy of multiple links and multiple targets is expected to achieve a better curative effect. The aim of this study is to investigate the brain targeting of a drug modified by chitosan, based on the new nanodrug delivery system for treating Alzheimer's disease developed by the research group.</p><p><strong>Materials and methods: </strong>Chitosan with good biocompatibility, biosorption, and degradation products that can protect and promote the regeneration of nerve cells was selected to combine with galantamine, a natural representative cholinesterase inhibitor, to develop a new nano drug delivery system for nasal delivery of anti-Alzheimer's disease with a multi-target synergistic effect. Synchronous analysis was conducted on the blood and brain tissue drug concentrations after intravenous and nasal administration of the original drug solution and system solution. The brain targeting index (DTI) is used to evaluate the brain targeting effect of the nano-drug delivery system after intranasal administration.</p><p><strong>Results: </strong>The blood concentration of galantamine original drug solution and galantamine system solution after intravenous injection and nasal show that in the two administration methods of intravenous injection and nasal administration, under the same administration method, the time point of the system reaching the highest blood drug concentration is much higher than that of the original drug. The content of galantamine in plasma samples and tissue samples indicate that after intravenous administration and intranasal administration of the galantamine system, at the same time point, the drug concentration in brain tissue was far greater than that of the original drug of galantamine, and the duration was also longer. The concentration of drugs in brain tissue decreased gradually in the order of olfactory bulb, olfactory tract, brain, and cerebellum. In the brain tissues of the olfactory bulb, olfactory tract, cerebrum, and cerebellum, the drug concentration of the galantamine system after intravenous injection is lower than that after nasal administration.</p><p><strong>Conclusions: </strong>This study concludes that compared with the original drug solution, the nano drug delivery system has significant brain targeting for nasal administration, and intravenous injection also has brain targeting. In the olfactory bulb, olfactory tract, brain, and cerebellum, the brain targeting index at the olfactory bulb is the highest, and the targeting is the best.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biochemical parameters and clinical outcomes of carbon monoxide poisoning in special groups: children, pregnant women, and the elderly. 特殊群体(儿童、孕妇和老人)一氧化碳中毒的生化指标和临床结果。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.26355/eurrev_202406_36376
A Vural, T Dolanbay, M Ozçelik, Z Y Oztorun, N Ardıc, A B Vural, M C Altay

Objective: Carbon monoxide (CO), a toxic gas, poses a significant threat to human health. Children, pregnant women, and elderly individuals are particularly vulnerable to this toxicity. This study aims to evaluate the demographic and clinical characteristics of pediatric, pregnant, and geriatric patients.

Patients and methods: The study included pediatric, pregnant, and geriatric patients with a confirmed diagnosis of CO poisoning, excluding those with complete file data and those with carboxyhemoglobin (COHb) levels below 5% (for children and pregnant patients) and 10% (for elderly patients). Patients aged < 18 years, > 65 years, and pregnant patients admitted to the adult and pediatric emergency departments were included in the study; statistical analyses were conducted using SPSS Inc., with a p-value of < 0.05 considered statistically significant.

Results: For pediatric patients, a statistically significant difference was observed between the two groups in terms of their main complaints, which were primarily attributed to neurological and general symptoms. A positive correlation was found between follow-up time and several factors, including white blood cell (WBC) count and troponin, lactate, lactate dehydrogenase (LDH), and COHb levels. For pregnant patients, no in-hospital mortality was observed in the patients included in this study. A significant negative correlation was identified between age and both COHb and hemoglobin (Hb) levels. A strong positive correlation was found between the COHb levels and hospital follow-up time. For elderly patients, no significant differences were found between the two treatment modalities. Notably, higher COHb levels on admission were associated with a more fatal in-hospital course, with COHb levels > 40% of all patients requiring intubation.

Conclusions: Vulnerable populations are at increased risk of exposure to CO, and the study results emphasize the necessity of heightened awareness and preventive measures to safeguard these individuals from CO poisoning.

目标:一氧化碳 (CO) 是一种有毒气体,对人类健康构成严重威胁。儿童、孕妇和老年人尤其容易受到这种毒性的影响。本研究旨在评估小儿、孕妇和老年患者的人口统计学和临床特征:研究对象包括确诊为一氧化碳中毒的儿童、孕妇和老年患者,但不包括档案数据完整的患者以及碳氧血红蛋白(COHb)水平低于 5%(儿童和孕妇患者)和 10%(老年患者)的患者。成人和儿科急诊室收治的年龄小于 18 岁、大于 65 岁的患者和孕妇均被纳入研究范围;统计分析采用 SPSS Inc:就儿科患者而言,两组患者的主要主诉在统计学上有显著差异,主要是神经系统症状和全身症状。随访时间与白细胞(WBC)计数、肌钙蛋白、乳酸、乳酸脱氢酶(LDH)和 COHb 水平等几个因素呈正相关。对于妊娠患者,本研究中未观察到院内死亡率。研究发现,年龄与 COHb 和血红蛋白(Hb)水平之间存在明显的负相关。COHb 水平与住院随访时间之间存在很强的正相关性。对于老年患者,两种治疗方式之间没有发现明显差异。值得注意的是,入院时较高的 COHb 水平与较致命的住院过程有关,在所有需要插管的患者中,COHb 水平大于 40% 的患者需要插管:结论:易感染人群接触一氧化碳的风险增加,研究结果表明,有必要提高对一氧化碳中毒的认识,并采取预防措施保护这些人群。
{"title":"Biochemical parameters and clinical outcomes of carbon monoxide poisoning in special groups: children, pregnant women, and the elderly.","authors":"A Vural, T Dolanbay, M Ozçelik, Z Y Oztorun, N Ardıc, A B Vural, M C Altay","doi":"10.26355/eurrev_202406_36376","DOIUrl":"https://doi.org/10.26355/eurrev_202406_36376","url":null,"abstract":"<p><strong>Objective: </strong>Carbon monoxide (CO), a toxic gas, poses a significant threat to human health. Children, pregnant women, and elderly individuals are particularly vulnerable to this toxicity. This study aims to evaluate the demographic and clinical characteristics of pediatric, pregnant, and geriatric patients.</p><p><strong>Patients and methods: </strong>The study included pediatric, pregnant, and geriatric patients with a confirmed diagnosis of CO poisoning, excluding those with complete file data and those with carboxyhemoglobin (COHb) levels below 5% (for children and pregnant patients) and 10% (for elderly patients). Patients aged < 18 years, > 65 years, and pregnant patients admitted to the adult and pediatric emergency departments were included in the study; statistical analyses were conducted using SPSS Inc., with a p-value of < 0.05 considered statistically significant.</p><p><strong>Results: </strong>For pediatric patients, a statistically significant difference was observed between the two groups in terms of their main complaints, which were primarily attributed to neurological and general symptoms. A positive correlation was found between follow-up time and several factors, including white blood cell (WBC) count and troponin, lactate, lactate dehydrogenase (LDH), and COHb levels. For pregnant patients, no in-hospital mortality was observed in the patients included in this study. A significant negative correlation was identified between age and both COHb and hemoglobin (Hb) levels. A strong positive correlation was found between the COHb levels and hospital follow-up time. For elderly patients, no significant differences were found between the two treatment modalities. Notably, higher COHb levels on admission were associated with a more fatal in-hospital course, with COHb levels > 40% of all patients requiring intubation.</p><p><strong>Conclusions: </strong>Vulnerable populations are at increased risk of exposure to CO, and the study results emphasize the necessity of heightened awareness and preventive measures to safeguard these individuals from CO poisoning.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction Note: LncRNA UCA1 affects osteoblast proliferation and differentiation by regulating BMP-2 expression. 撤稿说明:LncRNA UCA1通过调节BMP-2的表达影响成骨细胞的增殖和分化。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.26355/eurrev_202406_36397
R-F Zhang, J-W Liu, S-P Yu, D Sun, X-H Wang, J-S Fu, Z Xie

The article "LncRNA UCA1 affects osteoblast proliferation and differentiation by regulating BMP-2 expression", by R.-F. Zhang, J.-W. Liu, S.-P. Yu, D. Sun, X.-H. Wang, J.-S. Fu, Z. Xie, published in Eur Rev Med Pharmacol Sci 2019; 23 (16): 6774-6782-DOI: 10.26355/eurrev_201908_18715-PMID: 31486475 has been retracted by the authors for the following reasons: - The data presented in the manuscript require further validation, which may affect the results. After careful consideration, we have decided to withdraw it to ensure its reliability and reproducibility. All authors concur with this decision. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/18715.

文章 "LncRNA UCA1通过调控BMP-2的表达影响成骨细胞的增殖和分化",作者:R.-F. Zhang, J.-W.Zhang, J.-W.Liu, S.-P. Yu, D. Sun, X.-H. Wang, J.-S.Wang, J.-S. Fu, Z. XieFu, Z. Xie》,发表于《Eur Rev Med Pharmacol Sci 2019; 23 (16):6774-6782-DOI: 10.26355/eurrev_201908_18715-PMID: 31486475 已被作者撤回,原因如下:- 手稿中提供的数据需要进一步验证,这可能会影响结果。经过慎重考虑,我们决定撤回该稿件,以确保其可靠性和可重复性。所有作者均同意这一决定。这篇文章已被撤回。出版商对此造成的不便深表歉意。https://www.europeanreview.org/article/18715。
{"title":"Retraction Note: LncRNA UCA1 affects osteoblast proliferation and differentiation by regulating BMP-2 expression.","authors":"R-F Zhang, J-W Liu, S-P Yu, D Sun, X-H Wang, J-S Fu, Z Xie","doi":"10.26355/eurrev_202406_36397","DOIUrl":"https://doi.org/10.26355/eurrev_202406_36397","url":null,"abstract":"<p><p>The article \"LncRNA UCA1 affects osteoblast proliferation and differentiation by regulating BMP-2 expression\", by R.-F. Zhang, J.-W. Liu, S.-P. Yu, D. Sun, X.-H. Wang, J.-S. Fu, Z. Xie, published in Eur Rev Med Pharmacol Sci 2019; 23 (16): 6774-6782-DOI: 10.26355/eurrev_201908_18715-PMID: 31486475 has been retracted by the authors for the following reasons: - The data presented in the manuscript require further validation, which may affect the results. After careful consideration, we have decided to withdraw it to ensure its reliability and reproducibility. All authors concur with this decision. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/18715.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction Note: Correlation between COVID-19 and air pollution: the effects of PM2.5 and PM10 on COVID-19 outcomes. 撤稿说明:COVID-19与空气污染的相关性:PM2.5和PM10对COVID-19结果的影响。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.26355/eurrev_202406_36393
E Kalluçi, E Noka, K Bani, X Dhamo, I Alimehmeti, K Dhuli, G Madeo, C Micheletti, G Bonetti, C Zuccato, E Borghetti, G Marceddu, M Bertelli

The article "Correlation between COVID-19 and air pollution: the effects of PM2.5 and PM10 on COVID-19 outcomes", by E. Kalluçi, E. Noka, K. Bani, X. Dhamo, I. Alimehmeti, K. Dhuli, G. Madeo, C. Micheletti, G. Bonetti, C. Zuccato, E. Borghetti, G. Marceddu, M. Bertelli, published in Eur Rev Med Pharmacol Sci 2023; 27 (6 Suppl): 39-47-DOI: 10.26355/eurrev_202312_34688-PMID: 38112947 has been retracted by the Editor in Chief. Following concerns raised on PubPeer, the Editor in Chief has initiated an investigation to evaluate the validity of the results. Despite the authors' prompt responses to the identified issues, the Editor in Chief has decided to withdraw the article due to significant errors in the text and final statements, as well as undisclosed conflicts of interest. The Publisher apologizes if these concerns have not been detected during the review process. The authors have been informed about the retraction. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/34688.

E. Kalluçi、E. Noka、K. Bani、X. Dhamo、I.Alimehmeti, K. Dhuli, G. Madeo, C. Micheletti, G. Bonetti, C. Zuccato, E. Borghetti, G. Marceddu, M. Bertelli, 发表于 Eur Rev Med Pharmacol Sci 2023; 27 (6 Suppl):39-47-DOI: 10.26355/eurrev_202312_34688-PMID: 38112947 已被主编撤回。根据 PubPeer 上提出的问题,主编已启动调查,以评估结果的有效性。尽管作者对发现的问题做出了及时回应,但由于文章正文和最后声明中的重大错误以及未披露的利益冲突,主编决定撤回该文章。如果在审稿过程中没有发现这些问题,出版商深表歉意。作者已收到撤稿通知。本文已被撤稿。出版商对由此造成的不便深表歉意。https://www.europeanreview.org/article/34688。
{"title":"Retraction Note: Correlation between COVID-19 and air pollution: the effects of PM2.5 and PM10 on COVID-19 outcomes.","authors":"E Kalluçi, E Noka, K Bani, X Dhamo, I Alimehmeti, K Dhuli, G Madeo, C Micheletti, G Bonetti, C Zuccato, E Borghetti, G Marceddu, M Bertelli","doi":"10.26355/eurrev_202406_36393","DOIUrl":"https://doi.org/10.26355/eurrev_202406_36393","url":null,"abstract":"<p><p>The article \"Correlation between COVID-19 and air pollution: the effects of PM2.5 and PM10 on COVID-19 outcomes\", by E. Kalluçi, E. Noka, K. Bani, X. Dhamo, I. Alimehmeti, K. Dhuli, G. Madeo, C. Micheletti, G. Bonetti, C. Zuccato, E. Borghetti, G. Marceddu, M. Bertelli, published in Eur Rev Med Pharmacol Sci 2023; 27 (6 Suppl): 39-47-DOI: 10.26355/eurrev_202312_34688-PMID: 38112947 has been retracted by the Editor in Chief. Following concerns raised on PubPeer, the Editor in Chief has initiated an investigation to evaluate the validity of the results. Despite the authors' prompt responses to the identified issues, the Editor in Chief has decided to withdraw the article due to significant errors in the text and final statements, as well as undisclosed conflicts of interest. The Publisher apologizes if these concerns have not been detected during the review process. The authors have been informed about the retraction. This article has been retracted. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/34688.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The six scoring systems' prognostic value in predicting 24-hour mortality in septic patients. 六种评分系统在预测脓毒症患者 24 小时死亡率方面的预后价值。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.26355/eurrev_202406_36462
M Djikic, M Milenkovic, M Stojadinovic, T Miladinovic, D Gujanicic, I Milicevic-Nesic, B Uzelac, M Laban, D Markovic

Objective: The use of scoring systems contributes to the faster identification of septic patients, especially those at a high risk of a fatal outcome. The best scoring system does not exist, so the search for the optimal one is always current. The aim of this study is to estimate the prognostic value of the six scoring systems in predicting 24-hour mortality among septic patients presented at the emergency department.

Patients and methods: An observational retrospective study was conducted in the Emergency Triage Room (ETR) of the Emergency Center (EC) at the University Clinical Center of Serbia (UCCS) in Belgrade. Consecutive septic patients, according to the Sepsis-3 definition, with or without shock, presented to the ETR and then hospitalized in Intensive Care Units were included in the study. Mortality data within 24 h and on the 28th day were extracted from the Hospital information system or the National mortality database. Scoring systems including sequential organ failure assessment (SOFA), quick sequential organ failure assessment (qSOFA), systemic inflammatory response syndrome (SIRS), National early warning score (NEWS), sepsis patient evaluation in the emergency department (SPEED), and mortality in emergency department sepsis (MEDS) were analyzed for all patients utilizing the available data. The primary outcome of this study was death within 24 hours of triage. Receiver operating characteristic (ROC) analysis was used to determine the most effective scoring system. Lactate was then added to this system to enhance its predictive accuracy.

Results: Nineteen out of 120 patients included in the study (15.8%) experienced death within 24 hours of triage. The twenty-eight-day mortality rate was 55%. SOFA score demonstrated the highest predictive value for 24-hour mortality but was only moderately predictive overall, with an area under the receiver operating curve (AUC) of 0.755 (95% CI 0.625-0.885). SPEED, MEDS, and NEVS exhibited modest discriminatory power [0.673 (95% CI 0.543-0.803), 0.665 (95% CI 0.536-0.794), 0.630 (95% CI 0.528-0.724)], while SIRS and qSOFA remained insignificant in predicting 24-hour mortality. The predictive value of the SOFA score was increased by the addition of lactate (AUC 0.865, 95% CI 0.736-0.995; p=0.0081). All scores demonstrated better and satisfactory predictive power for 28-day mortality.

Conclusions: SOFA, with the addition of lactate, is a complex but reliable tool for the early stratification of septic patients who are presenting at an emergency department.

目的:使用评分系统有助于更快地识别脓毒症患者,尤其是那些极有可能出现致命结果的患者。目前还不存在最好的评分系统,因此一直在寻找最佳评分系统。本研究旨在估算六种评分系统在预测急诊科脓毒症患者 24 小时死亡率方面的预后价值:在贝尔格莱德塞尔维亚大学临床中心(UCCS)急诊中心(EC)的急诊分诊室(ETR)进行了一项观察性回顾研究。根据败血症-3的定义,研究对象包括在急诊分诊室就诊、随后在重症监护病房住院的连续败血症患者,无论患者是否出现休克。研究人员从医院信息系统或国家死亡率数据库中提取了 24 小时内和 28 天内的死亡率数据。利用现有数据分析了所有患者的评分系统,包括序贯器官衰竭评估(SOFA)、快速序贯器官衰竭评估(qSOFA)、全身炎症反应综合征(SIRS)、国家预警评分(NEWS)、急诊科脓毒症患者评估(SPEED)和急诊科脓毒症死亡率(MEDS)。本研究的主要结果是分诊后 24 小时内的死亡。采用接收者操作特征(ROC)分析来确定最有效的评分系统。然后将乳酸添加到该系统中,以提高其预测准确性:在 120 名参与研究的患者中,有 19 人(15.8%)在分诊后 24 小时内死亡。二十八天的死亡率为 55%。SOFA 评分对 24 小时死亡率的预测价值最高,但总体预测价值一般,接收者操作曲线下面积 (AUC) 为 0.755(95% CI 0.625-0.885)。SPEED、MEDS和NEVS显示出适度的鉴别力[0.673(95% CI 0.543-0.803)、0.665(95% CI 0.536-0.794)、0.630(95% CI 0.528-0.724)],而SIRS和qSOFA在预测24小时死亡率方面仍不显著。加入乳酸后,SOFA 评分的预测价值有所提高(AUC 0.865,95% CI 0.736-0.995;P=0.0081)。所有评分对28天死亡率的预测能力都较好,令人满意:加入乳酸的 SOFA 是一种复杂但可靠的工具,可用于对急诊科就诊的脓毒症患者进行早期分层。
{"title":"The six scoring systems' prognostic value in predicting 24-hour mortality in septic patients.","authors":"M Djikic, M Milenkovic, M Stojadinovic, T Miladinovic, D Gujanicic, I Milicevic-Nesic, B Uzelac, M Laban, D Markovic","doi":"10.26355/eurrev_202406_36462","DOIUrl":"10.26355/eurrev_202406_36462","url":null,"abstract":"<p><strong>Objective: </strong>The use of scoring systems contributes to the faster identification of septic patients, especially those at a high risk of a fatal outcome. The best scoring system does not exist, so the search for the optimal one is always current. The aim of this study is to estimate the prognostic value of the six scoring systems in predicting 24-hour mortality among septic patients presented at the emergency department.</p><p><strong>Patients and methods: </strong>An observational retrospective study was conducted in the Emergency Triage Room (ETR) of the Emergency Center (EC) at the University Clinical Center of Serbia (UCCS) in Belgrade. Consecutive septic patients, according to the Sepsis-3 definition, with or without shock, presented to the ETR and then hospitalized in Intensive Care Units were included in the study. Mortality data within 24 h and on the 28th day were extracted from the Hospital information system or the National mortality database. Scoring systems including sequential organ failure assessment (SOFA), quick sequential organ failure assessment (qSOFA), systemic inflammatory response syndrome (SIRS), National early warning score (NEWS), sepsis patient evaluation in the emergency department (SPEED), and mortality in emergency department sepsis (MEDS) were analyzed for all patients utilizing the available data. The primary outcome of this study was death within 24 hours of triage. Receiver operating characteristic (ROC) analysis was used to determine the most effective scoring system. Lactate was then added to this system to enhance its predictive accuracy.</p><p><strong>Results: </strong>Nineteen out of 120 patients included in the study (15.8%) experienced death within 24 hours of triage. The twenty-eight-day mortality rate was 55%. SOFA score demonstrated the highest predictive value for 24-hour mortality but was only moderately predictive overall, with an area under the receiver operating curve (AUC) of 0.755 (95% CI 0.625-0.885). SPEED, MEDS, and NEVS exhibited modest discriminatory power [0.673 (95% CI 0.543-0.803), 0.665 (95% CI 0.536-0.794), 0.630 (95% CI 0.528-0.724)], while SIRS and qSOFA remained insignificant in predicting 24-hour mortality. The predictive value of the SOFA score was increased by the addition of lactate (AUC 0.865, 95% CI 0.736-0.995; p=0.0081). All scores demonstrated better and satisfactory predictive power for 28-day mortality.</p><p><strong>Conclusions: </strong>SOFA, with the addition of lactate, is a complex but reliable tool for the early stratification of septic patients who are presenting at an emergency department.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author Correction: Intravenous N-acetylcysteine in respiratory disease with abnormal mucus secretion. 作者更正:静脉注射 N-乙酰半胱氨酸治疗粘液分泌异常的呼吸系统疾病。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.26355/eurrev_202406_36388
W Tang, D Zhu, F Wu, J-F Xu, J-P Yang, Z-P Deng, X-B Chen, A Papi, J-M Qu

Eur Rev Med Pharmacol Sci 2023; 27 (11): 5119-5127-DOI: 10.26355/eurrev_202306_32628-PMID: 37318485, published online on June 13, 2023. After publication, the authors have found some mistakes. This erratum corrects the following: In Figure 1, "4 withdrawal" has been corrected into "7 withdrawal" and "95 completed study" has been corrected into "97 corrected study" In the "Efficacy" paragraph at page 5123, "1.0 in the placebo group" has been corrected into "-1.0 in the placebo group". The legend of Table V has been corrected as follows: Table V. Published clinical studies of the mucolytic and expectorant efficacy of IV NAC in respiratory diseases. In Table V, the data regarding the Treatment groups (duration) by Grassi et al5 have been corrected as follows: NAC oral 200 mg TID NAC IM 300 mg BID NAC IV 500 mg OD (6 days) In Table V, the data regarding the Treatment groups (duration) by Henneghien et al8 have been corrected as follows: NAC oral 200 mg TID NAC IV 300 mg TID (3-10 days) NAC IV 500 mg BID (12 days) There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/32628.

Eur Rev Med Pharmacol Sci 2023; 27 (11): 5119-5127-DOI: 10.26355/eurrev_202306_32628-PMID: 37318485,2023年6月13日在线发表。文章发表后,作者发现了一些错误。本勘误更正如下:在图 1 中,"4 次退出 "更正为 "7 次退出","95 次完成研究 "更正为 "97 次更正研究"。在第 5123 页的 "疗效 "段中,"安慰剂组 1.0 "更正为 "安慰剂组-1.0"。表 V 的图例更正如下:表 V.已发表的关于静脉注射 NAC 对呼吸道疾病的粘液溶解和祛痰疗效的临床研究。表 V 中,Grassi 等人5 的治疗组(持续时间)数据更正如下:NAC 口服 200 毫克 TID NAC IM 300 毫克 BID NAC IV 500 毫克 OD(6 天) 在表 V 中,Henneghien 等8 的治疗组(持续时间)数据更正如下:NAC IV 300 mg TID (3-10 天) NAC IV 500 mg BID (12 天) 对本文进行了修正。https://www.europeanreview.org/article/32628。
{"title":"Author Correction: Intravenous N-acetylcysteine in respiratory disease with abnormal mucus secretion.","authors":"W Tang, D Zhu, F Wu, J-F Xu, J-P Yang, Z-P Deng, X-B Chen, A Papi, J-M Qu","doi":"10.26355/eurrev_202406_36388","DOIUrl":"https://doi.org/10.26355/eurrev_202406_36388","url":null,"abstract":"<p><p>Eur Rev Med Pharmacol Sci 2023; 27 (11): 5119-5127-DOI: 10.26355/eurrev_202306_32628-PMID: 37318485, published online on June 13, 2023. After publication, the authors have found some mistakes. This erratum corrects the following: In Figure 1, \"4 withdrawal\" has been corrected into \"7 withdrawal\" and \"95 completed study\" has been corrected into \"97 corrected study\" In the \"Efficacy\" paragraph at page 5123, \"1.0 in the placebo group\" has been corrected into \"-1.0 in the placebo group\". The legend of Table V has been corrected as follows: Table V. Published clinical studies of the mucolytic and expectorant efficacy of IV NAC in respiratory diseases. In Table V, the data regarding the Treatment groups (duration) by Grassi et al5 have been corrected as follows: NAC oral 200 mg TID NAC IM 300 mg BID NAC IV 500 mg OD (6 days) In Table V, the data regarding the Treatment groups (duration) by Henneghien et al8 have been corrected as follows: NAC oral 200 mg TID NAC IV 300 mg TID (3-10 days) NAC IV 500 mg BID (12 days) There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/32628.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sound therapy in patients with tinnitus: traditional sound generators vs. mobile apps. 耳鸣患者的声音疗法:传统发声器与移动应用程序。
IF 3.3 4区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.26355/eurrev_202406_36384
G Altissimi, A Musacchio, A Pace, A Greco, G Magliulo, G Iagnocco, A Ciofalo, M Ralli

Objective: Tinnitus Retraining Therapy (TRT) is a rehabilitation approach for tinnitus that is currently considered an effective treatment with an elevated response rate. TRT is usually delivered through sound generators; however, they are often difficult to find and expensive. Recently, mobile apps have been proposed for TRT. This study aims to verify the effectiveness of TRT performed using mobile apps in reducing the adverse effects of tinnitus on the quality of life.

Patients and methods: A total of 80 patients affected by tinnitus in category 0 (mild tinnitus) and category 1 (moderate tinnitus), according to the Jastreboff classification, were included in the study. Patients of both classes were subsequently differentiated into two homogeneous groups; the first (Group A) was treated with a traditional sound generator, and the second (Group B) using a mobile app. The Tinnitus Handicap Inventory - the Italian version of the questionnaire - was used to investigate the impact of tinnitus on the quality of life in enrolled patients and evaluate their response to TRT.

Results: A significant improvement was found in THI scores in category 0 patients for both sound generator and mobile app groups; no difference was found between the two-treatment delivery technology (-1.186, p=0.783); conversely, tinnitus improvements in category 1 patients were only reported for subjects treated using a sound generator (-14.529, p<0.001), while no significant improvement was found in patients treated using the mobile app.

Conclusions: This study confirms the value of TRT, which in patients with mild tinnitus (category 0), can also be delivered through mobile apps with results comparable to traditional sound generators. Further studies are necessary to confirm the effects of the different tinnitus treatments available and improve the knowledge on this topic.

目的:耳鸣训练疗法(TRT)是一种治疗耳鸣的康复方法,目前被认为是一种反应率较高的有效治疗方法。耳鸣再训练疗法通常通过发声器进行,但发声器通常很难找到,而且价格昂贵。最近,有人提出了用于 TRT 的移动应用程序。本研究旨在验证使用手机应用程序进行 TRT 在减少耳鸣对生活质量的不良影响方面的有效性:本研究共纳入了 80 名耳鸣患者,根据 Jastreboff 分类法,他们分别属于 0 类(轻度耳鸣)和 1 类(中度耳鸣)。这两类患者随后被分为两组,第一组(A 组)使用传统发声器,第二组(B 组)使用移动应用程序。耳鸣障碍量表(意大利语版问卷)用于调查耳鸣对入组患者生活质量的影响,并评估他们对 TRT 的反应:结果:在发声器组和手机应用组中,0类患者的THI评分均有明显改善;两种治疗技术之间没有差异(-1.186,p=0.783);相反,只有使用发声器治疗的受试者的1类患者耳鸣症状有所改善(-14.529,p):本研究证实了 TRT 的价值,对于轻度耳鸣(0 类)患者,也可通过移动应用程序进行治疗,效果与传统发声器不相上下。有必要开展进一步研究,以确认不同耳鸣治疗方法的效果,并增进对这一主题的了解。
{"title":"Sound therapy in patients with tinnitus: traditional sound generators vs. mobile apps.","authors":"G Altissimi, A Musacchio, A Pace, A Greco, G Magliulo, G Iagnocco, A Ciofalo, M Ralli","doi":"10.26355/eurrev_202406_36384","DOIUrl":"https://doi.org/10.26355/eurrev_202406_36384","url":null,"abstract":"<p><strong>Objective: </strong>Tinnitus Retraining Therapy (TRT) is a rehabilitation approach for tinnitus that is currently considered an effective treatment with an elevated response rate. TRT is usually delivered through sound generators; however, they are often difficult to find and expensive. Recently, mobile apps have been proposed for TRT. This study aims to verify the effectiveness of TRT performed using mobile apps in reducing the adverse effects of tinnitus on the quality of life.</p><p><strong>Patients and methods: </strong>A total of 80 patients affected by tinnitus in category 0 (mild tinnitus) and category 1 (moderate tinnitus), according to the Jastreboff classification, were included in the study. Patients of both classes were subsequently differentiated into two homogeneous groups; the first (Group A) was treated with a traditional sound generator, and the second (Group B) using a mobile app. The Tinnitus Handicap Inventory - the Italian version of the questionnaire - was used to investigate the impact of tinnitus on the quality of life in enrolled patients and evaluate their response to TRT.</p><p><strong>Results: </strong>A significant improvement was found in THI scores in category 0 patients for both sound generator and mobile app groups; no difference was found between the two-treatment delivery technology (-1.186, p=0.783); conversely, tinnitus improvements in category 1 patients were only reported for subjects treated using a sound generator (-14.529, p<0.001), while no significant improvement was found in patients treated using the mobile app.</p><p><strong>Conclusions: </strong>This study confirms the value of TRT, which in patients with mild tinnitus (category 0), can also be delivered through mobile apps with results comparable to traditional sound generators. Further studies are necessary to confirm the effects of the different tinnitus treatments available and improve the knowledge on this topic.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":null,"pages":null},"PeriodicalIF":3.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European review for medical and pharmacological sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1